Inogen, Inc. (NASDAQ:INGN) Shares Bought by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC raised its stake in Inogen, Inc. (NASDAQ:INGN) by 84.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,288 shares of the medical technology company’s stock after purchasing an additional 2,419 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Inogen were worth $29,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of INGN. Paradigm Capital Management Inc. NY acquired a new stake in shares of Inogen in the third quarter valued at about $52,000. SG Americas Securities LLC purchased a new position in Inogen in the 3rd quarter worth approximately $52,000. Quadrature Capital Ltd acquired a new stake in Inogen in the third quarter valued at approximately $79,000. Carnegie Capital Asset Management LLC purchased a new stake in shares of Inogen during the fourth quarter valued at approximately $96,000. Finally, Olympiad Research LP acquired a new position in shares of Inogen during the fourth quarter worth $97,000. Institutional investors and hedge funds own 89.94% of the company’s stock.

Inogen Stock Up 1.7 %

Shares of INGN traded up $0.12 during trading on Friday, reaching $7.15. The company’s stock had a trading volume of 148,016 shares, compared to its average volume of 299,941. The company has a market cap of $168.38 million, a price-to-earnings ratio of -1.62 and a beta of 1.10. The company has a fifty day moving average of $7.16 and a two-hundred day moving average of $6.45. Inogen, Inc. has a twelve month low of $4.13 and a twelve month high of $13.86.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, February 27th. The medical technology company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.49). Inogen had a negative net margin of 32.46% and a negative return on equity of 38.98%. The company had revenue of $75.90 million during the quarter, compared to analyst estimates of $78.09 million. As a group, equities analysts forecast that Inogen, Inc. will post -2.56 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. William Blair raised shares of Inogen from a “market perform” rating to an “outperform” rating in a report on Thursday, February 15th. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a research report on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, Inogen has a consensus rating of “Hold” and an average price target of $7.50.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.